tldrdailynews.com logo

Pfizer Abandons Obesity Pill Development Amidst Side Effect Concerns

1 min read
Source: Financial Times
TL;DR Summary

Pfizer has announced that it is dropping its plan to develop a twice-daily obesity pill due to significant side effects. The pharmaceutical company had been conducting clinical trials for the medication, but the adverse reactions experienced by participants led to the decision to discontinue its development.

Topics:top-news#drug-development#health#medication#obesity#pfizer#side-effects
Share this article
  1. Pfizer drops plan for twice-daily obesity pill due to side effects  Financial Times
  2. Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects  CNBC
  3. Pfizer Stops Developing Weight-Loss Pill  Bloomberg Television
  4. Pfizer slumps; pulls 2-dose obesity-drug study following patient reactions  TheStreet
  5. Pfizer's stock falls 4% after halting trial of obesity drug due to side effects  MarketWatch

Reading Insights

Total Reads

0

Unique Readers

19

Time Saved

0 min

vs 1 min read

Condensed

50%

92 → 46 words

Want the full story? Read the original article

Read on Financial Times